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Abstract. Background: Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour of 
the infancy and the first decade of life. It is locally aggressive and potentially life threatening 
when associated with consumptive coagulopathy, known as Kasabach-Merritt syndrome (KMS). 
No consensus or guideline for the therapy has been reached because of the lack of prospective 
trials, and the different standard care suggestions are based on retrospective case series.  
Case report: We report the case of a 9-month-old male with KHE and KMS in which the initial 
response, obtained with prednisone and vincristine, was subsequently consolidated and 
strengthened by long-term treatment with sirolimus, a mTOR inhibitor. A summary of the 
published data is presented as well. 
Conclusions: The inhibition of mTOR pathway represents the most important therapeutic 
innovation introduced in the last few years for KHE. Our case shows the effectiveness and good 
tolerance of long-term therapy with sirolimus. 
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endothelioma (KHE) is a rare vascular tumour of 
the infancy and the first decade of life. KHE 
shows no sex predilection, is locally aggressive 
and potentially life threatening when associated 
with consumptive coagulopathy known as 
Kasabach-Merritt syndrome (KMS). KHE has an 
incidence of 0.7/100.000/year,1 and it can appear 
anywhere over the body with a wide range of 
clinical presentations. Macroscopically KHE is 
characterised by the presence of abundant vascular 
structures that infiltrate the surrounding soft 
tissues, and it is structured as a tender mass that 
causes pain when platelets congest within the 
vessels, and coagulation cascade is activated. 
Tumour nodules have irregular borders and they 
are composed of fascicles of spindle endothelial 
cells which are positive for vascular markers like 
CD31 and CD34, and negative for Glut1, with a 
low Ki67 proliferative index, rare mitosis, no 
nuclear atypia, no necrosis. KHE shows no 
tendency to metastasize.2 KMS is usually 
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associated with a reduction of platelets count and 
haemoglobin, a lengthening of prothrombin time 
(PT), partial thromboplastin time (PTT), and to a 
reduction of fibrinogen. No consensus or guideline 
for the therapy has been reached because of the 
lack of prospective trials, and the different 
standard care suggestions are based on 
retrospective case series. We report a severe case 
of KHE with KMS successfully treated with 
prednisone and vincristine, used to induce the 
initial response and subsequently consolidated and 
strengthened by long-term treatment with 
sirolimus. The inhibition of mTOR pathway by 
sirolimus is an important therapeutic innovation 
introduced in the last few years, and a review of 
the published data is discussed. 
 
Case Report. A 9-month-old male was admitted 
to the emergency department several times in three 
months for respiratory and urinary tract infections, 
constipation, recurrent abdominal pain with 
globose abdomen, and failure to thrive. The blood 
exams showed a recurrent thrombocytopenia 
interpreted as resulting from infections. Screening 
for celiac disease was negative. In the last access 
to the emergency department blood exams showed 
thrombocytopenia (110 x109/L) and anaemia (Hb 
8,9 g/dl) with white blood cell 8.3 x109/L, PT 1.26 
(n.v 0.80-1.17), PTT 1.17 (v.n 0.80-1.20), 
fibrinogen 0.83 g/L (n.v 2-4), D-dimer >10.000 
mcg/L (n.v < 0,25), antithrombin III 100% (n.v 
70-130). In the following weeks, he manifested a 
progressive decrease in the number of platelets, 
with a minimum value of 9 x 109/L. 
An ultrasound of the abdomen revealed a solid 
mass of about 6 x 2,3 cm in the retroperitoneal 
space, without clear margin, locally spread around 
the mesenteric vessels’ origins. The lesion was 
confirmed by magnetic resonance imaging (MRI) 
(Figure 1). A biopsy was performed: the 
histological features (Figure 2) and the 
immunophenotype with CD 31 (JC/70A) +, CD 34 
(QBEND/10)+, GLUT1 -/+, PODOPLANIN (D2-
40) +, PROTEIN S100 -, Herpes virus 8 (13B10) - 
were diagnostic for KHE and the clinical and 
laboratory features were indicative of KMS. The 
child started a 6-week therapy with prednisone at 
the dose of 2 mg/kg/d (with a slow tapering), an 8-
week course of vincristine (0,05 mg/kg/week) 
associated with sirolimus (3 mg/m2), modulated to 
maintain a blood concentration within the 
therapeutic range of 7,5-10 ng/ml. During the 
following months, there was a progressive clinical 
improvement with a 4 kg weight increase in 5 
months. Platelet count increased to > 50 x109/L 
after 15 days of therapy and normalized (> 150 
x109/L) after 4 months. As of 31st January 2018, 
the patient was being treated with sirolimus for 20 
months without any clinical or biochemical side 
effects or infection complication. The MRI 
performed at 1, 9, 16 months showed a progressive 
reduction of the mass (Figure 1).  
 
 
Figure 1. Abdominal MRI performed at 1, 9, 16 months. 
 
(A) MRI at the diagnosis. Solid tissue hypointense on T2-weighted 
images with post-contrast enhancement extended in the 
retroperitoneal area surrounding all upper abdominal vessels, 
adrenal glands and the left renal hilum (61x12 mm, black arrows). 
Lesions with the same characteristics also interest the hepatic hilum 
(36x12mm, white arrow) and the mesenteric adipose tissue. Left 
kidney enlarged with pyelectasis. Pancreas enlarged with areas 
showing post-contrast enhancement at the body-tail level. 
Progressive reduction in mass size after 1 month (B), 9 months (C) 
and 19 months (D). 
 
Figure 2. Biopsy histological features. 
 
Hematoxylin Eosin 400X magnification. Proliferation of neoplastic 
spindle cells, sparsely forming capillaries with red blood cells 
inside. 
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Discussion. We report a case of  KHE  with  KMS 
that continues to respond to long-term treatment 
with sirolimus without side effects. We performed 
a review of the literature of all cases of KHE in 
patients under the age of 18 with the aim of 
defining typical characteristics of the disease. We 
analysed 42 papers1-3,8,9,11,12,15-49 including case 
reports, brief reports, case series, consensus, 
clinical letters, short communications, letters to 
 the editor, retrospective studies, reviews and 
research letters. Data are summarised in table 1. 
The number of patients with KHE is 89 even if in 
55% of cases the diagnosis is not supported by the 
histology. The most frequent sites are the 
extremities (43%). KMS is described in 59% of 
patients and it always occurs in the abdominal 
sites (100%). In nearly all cases it is already 
present at the diagnosis; when KMS is not present 
at the onset the risk to develop it over time is low. 
Moreover, KMS occurs in 87% of the masses > 5 
cm and 100% of those > 10 cm, suggesting that 
dimensions are related to the risk of developing 
KMS (Table 1). No guideline has been defined, 
and different therapeutic medical and surgical 
treatments have been used for KHE with and 
without KMS. Radical surgery is one of possible 
treatment, and in cases of KMS it can resolve the 
coagulopathy, but unfortunately, most of the 
lesions are not surgically attackable, or they are 
only partially resectable. Embolization and 
sclerotherapy are other techniques rarely used due 
to the difficulty to cannulate small vessels and 
because of the risk of complications3. 
Radiotherapy has proven to be effective, but it is 
limited by important side effects.4,5  Steroid 
therapy, even at high doses, is widely used for this 
type of pathology and the literature data showed 
that 65% of the patients took a steroid (table 1). 
The most commonly used steroid is 
methylprednisolone (dose of 2 mg/kg/day) 
followed by prednisone and dexamethasone. This 
therapy often gives good results, but it is burdened 
by significant side effects especially when used for 
long time.21,24,31,49 Vincristine is an effective 
chemotherapeutic drug, administered once a week 
at a dosage of 0.05 mg/kg/dose. Vincristine has 
been used in 34% of patients especially in 
association with steroid therapy in patients with 
KMS. Vincristine resulted effective although the 
complete remission was rare and the duration of 
therapy is limited by side effects.6,7,8 Propranolol 
has been shown to be effective in the treatment of 
KHE,9 but the use in monotherapy is not able to 
control the disease.3 Interferon, antiangiogenic 
drugs such as bevacizumab10 and aspirin11 have 
been tested. Sirolimus is a mTOR inhibitor that is 
a serine/threonine kinase regulated by 
phosphoinositide-3-kinase. It is an important 
therapeutic option that has been increasingly used 
in the last few years. It affects cell growth and 
angiogenesis; it is also a powerful 
immunosuppressor and an antitumoral drug.1,12 In 
multiple studies the effectiveness of the use of 
Sirolimus and other mTOR inhibitor has been 
described,3,12,13,14 proving to be particularly active 
in vascular and lymphoproliferative disorders. 
Moreover, the mTOR inhibitors can be used in 
monotherapy even for long periods, being able to 
control cases of the non-completely regressed 
disease, and in spite of the necessity of constant 
control of blood levels, they resulted manageable 
and with little side effect. Literature data reported 
in table 1 show that 17% of patients received 
mTOR inhibitors, especially as second-line 
therapy after the use of steroids, vincristine, and 
others.8,19,20,21 It has been administered for months 
every day, in some cases twice a day, modulating 
the dose according to blood concentration (range 
7-10 ng / ml).1,3,8,12,16,19,20,21,25,28,32,34,49 According 
to the data summarised in table 1,  the most used 
therapeutic schemes are: steroid + other (33%) and 
steroid + vincristine + other (18%). In our case, 
the initial therapy of vincristine and prednisone 
was combined with sirolimus to obtain a 
regression of the KMS. Long-term therapy with 
sirolimus has shown to be effective in controlling 
the disease without side effects.  
 
Conclusions. KHE is a locally aggressive tumor, 
and it is potentially life threatening when 
associated with consumptive coagulopathy known 
as KMS. Although there is no univocal consensus 
on the therapy, our case shows that in cases of 
KHE with KMS a multidrug therapy (steroid + 
vincristine + mTOR inhibitor) followed by 
maintenance with the mTOR inhibitor 
monotherapy is a valuable option, with effective 
disease control and no relevant side effects. Future 
studies are needed to validate this approach and 
define the best duration of treatment. 
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Table 1. Features of patients.  
TOTAL NUMBER OF PATIENTS 89 
SEX Number of patients (%) 
Female 28 (31,5) 
Male 28 (31,5) 
Unknown 33 (37) 
AGE Number of patients (%) 
≤ 1 y 72 (81) 
 1  to  ≤ 10 y 17 (19) 
> 10 y 0 
Medium  age 7 m 
Median age  2 m 
Minimun age  0 d 
Maximal age 8y 
SITE Number of patients (%) 
Extremities 38 (43) 
Head and neck 16 (18) 
Chest wall 9 (10) 
Mediastinal 13 (15) 
Abdominal wall 1 (1) 
Abdomen (deep) 5 (6) 
Retroperitoneum 7 (8) 
SIZE Number of patients (%) 
≤ 5 cm  10 (11) 
> 5 cm        
of which >= 10 cm 
31 (35) 
14 
Unknown 48 (54) 
HISTOLOGY Number of patients (%) 
Yes  (surgery R2^) 11 (12) 
Yes  (surgery R0^ – R1^) 29 (33) 
No   49 (55) 
KASABACH-MERRITT (KMS) Number of patients (%) 
Yes 53 (59) 
No  15 (17) 
Unknown  21 (24) 
At diagnosis 52* (58) 
KMS  for SITE and SIZE  Yes (%) No (%) Unknown (%) 
Extremities (tot 38) 26 (68) 9 (24) 3 (8) 
Head and neck (tot 16) 9 (56) 5 (31) 2 (12) 
Chest wall (tot 9) 6 (66) 1 (11) 2 (22) 
Mediastinal (tot 13) 1 (8) - 12 (92) 
Abdominal wall (tot 1) 1 (100) - - 
Abdomen (deep) (tot 5) 5 (100) - - 
Retroperitoneum (tot 7) 5 (71) - 2 (29) 
Size ≤ 5 cm (tot 10) 2(20) 7(70) 1(10) 
Size > 5 cm (tot 31)    
of which >= 10 cm (tot 14) 
27 (87) 
14 (100) 
4 (13) - 
Size Unknown (tot 48) 23 (48) 25 (52) - 
INITIAL SURGERY  Number of patients (%) 
Biopsy 11 (12) 





Amputation 2 (2) 
Unknown 49 (55) 
NON SURGICAL-THERAPY Number of patients (%) 
Steroid 58 (65) 
Vincristine (VCR) 30 (34) 
Sirolimus/Everolimus 15 (17) 
Schemes   
- No therapy/ not described 11 (12) 
- Steroid 2 (2) 
- Sirolimus  2 (2) 
- Other •  15 (17) 
- Steroid + VCR 1  (1) 
- Steroid + other •  29 (33) 
- VCR + Sirolimus + other •  2 (2) 
- Steroid + VCR + Sirolimus 3 (3) 
- Steroid + VCR + other •  16 (18) 
- Steroid + VCR + Sirolimus + other •  8 (9) 
SURVIVAL †  Number of patients (%) 
Alive  68 (76) 
Dead 3♣ (3) 
Unknown  18 (20) 
* for one patient data not available. ^ R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor. • Interferon 
(IFN), cyclophosphamide, propranolol, urea, embolization, gammaglobulin, ticlopidine. † Time of follow up not specified in the majority of 
cases. ♣ A 13-day- old patient with 8 cm mass at head/neck level, KMS, undergoing surgical exeresis, treated with steroid + INF. Died for 
multi-organ-failure 11 days after surgery. A 45-day-old patient with unknown size mediastinal mass, KMS, treated with steroid + VCR+ 
INF, unknown cause of death, A 3-months-old patient with unknown size mediastinal mass, KMS, treated with steroid+INF+radiotherapy, 
unknown cause of death. 
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